ADMA Biologics
ADMA
55 hedge funds and large institutions have $115M invested in ADMA Biologics in 2018 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 18 increasing their positions, 3 reducing their positions, and 9 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 3
244% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 9
62% more funds holding
Funds holding: 34 → 55 (+21)
48% more capital invested
Capital invested by funds: $78M → $115M (+$37.2M)
8.93% more ownership
Funds ownership: 46.16% → 55.09% (+8.9%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$13.5M |
| 2 |
BC
Broadfin Capital
New York
|
+$12.6M |
| 3 |
BlackRock
New York
|
+$4.64M |
| 4 |
CCM
Consonance Capital Management
New York
|
+$4.59M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$1.44M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.01M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$435K |
| 4 |
Goldman Sachs
New York
|
-$429K |
| 5 |
Millennium Management
New York
|
-$220K |
ADMA Hedge Fund Activity: Q2 2018 in Review
55 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q2 2018, worth a combined $115M — up 48% from $78M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ADMA positions and 9 closed out — a net gain of 22 holders — while 18 added to existing stakes and 3 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $13.5M. The largest seller was Highbridge Capital Management, exiting entirely with an estimated $1.44M sold.
- 55 institutional investors held ADMA Biologics (ADMA) as of Q2 2018, up from 34 in Q1 2018.
- Funds reported $115M of ADMA Biologics stock for Q2 2018, up 48% quarter-over-quarter.
- 31 funds opened new ADMA Biologics positions in Q2 2018 and 9 closed out, a net change of +22 holders.
- The largest ADMA Biologics buyer in Q2 2018 was Perceptive Advisors, an estimated $13.5M added.
- The largest ADMA Biologics seller in Q2 2018 was Highbridge Capital Management, an estimated $1.44M sold.
Based on aggregated 13F filings for Q2 2018.